United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Invests $699,000 in Hologic, Inc. (NASDAQ:HOLX)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 9,700 shares of the medical equipment provider’s stock, valued at approximately $699,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. General Partner Inc. bought a new stake in Hologic during the 4th quarter valued at approximately $26,000. Groupama Asset Managment grew its stake in Hologic by 9.9% in the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares in the last quarter. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its stake in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $60.80 on Wednesday. The firm has a market capitalization of $13.64 billion, a PE ratio of 19.18, a PEG ratio of 2.14 and a beta of 0.97. The stock’s fifty day moving average is $65.70 and its 200 day moving average is $73.66. Hologic, Inc. has a fifty-two week low of $60.34 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on HOLX. Needham & Company LLC cut Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. William Blair reiterated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Citigroup cut their target price on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.